cardiovascular
Cardiovascular Risk and GLP-1 Medications
GLP-1 medications provide powerful cardiovascular protection, reducing major adverse cardiovascular events by 20-26% in high-risk patients.
20-26%
MACE reduction
5-10 mmHg
Blood pressure reduction
39%
Stroke risk reduction
Cardiovascular Benefits
GLP-1 medications reduce cardiovascular risk through multiple pathways beyond weight loss. They improve endothelial function and reduce arterial inflammation. They lower blood pressure 5-10 mmHg systolic. They improve lipid profiles, reducing triglycerides 20-30% and increasing HDL. They reduce visceral fat, which drives cardiac risk. They improve heart rate variability and reduce arterial stiffness. The SELECT trial showed semaglutide reduced MACE by 20% in patients with obesity and CVD. SUSTAIN-6 demonstrated 26% reduction in cardiovascular events with semaglutide in diabetes patients.
Who Benefits Most
Patients with established cardiovascular disease, diabetes, or multiple risk factors benefit most. Those with obesity plus hypertension, dyslipidemia, or family history of heart disease see significant risk reduction. Even patients without diabetes experience cardiovascular benefits from weight loss and metabolic improvement.
Medications commonly used
Find providers who understand cardiovascular risk
Compare GLP-1 providers by clinical oversight, medication options, pricing, and local availability.
Related conditions